Showing 1–15 of 15 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Eskild Petersen, Martin Rao, Giuseppe Ippolito, Gina Gualano, Jeremiah Chakaya, et al.
… by TB by 2022, and to conduct research on new diagnostics, treatments and vaccines required to achieve global TB control (Tiberi et al., 2018Tiberi S. Petersen E. Maeurer M. Ntoumi F. Yeboa-Manu D. Mwaba P. et al.Taking forward the Stop TB Partnership and World Health Organizati…
Margherita Bracchi, Clare van Halsema, Frank A. Post, Funmi Awosusi, Alison Barbour, et al.
These guidelines are dedicated to the memory of Professor Stephen Lawn, a scientist and clinician whose pioneering work helped transform the management of TB in people living with HIV. The overall purpose of these guidelines is to help physicians manage adults with tuberculosis (…
Amish Talwar, Clarisse A. Tsang, Sandy F. Price, Robert Pratt, William L. Walker, et al.
…ntury without greatly increased investment in detection and treatment of latent TB infection (LTBI).1Menzies NA Cohen T Hill AN et al.Prospects for tuberculosis elimination in the United States: results of a transmission dynamic model.Am J Epidemiol. 2018; 187: 2011-2020Crossref …
Brett K, Dulong C, Severn M
…ing pulmonary TB., Individuals with TB are categorized into latent TB infection (LTBI) and active TB disease., LTBI refers to an individual who has the M. tuberculosis infection in which the bacteria are alive but are not currently causing active TB disease. Active TB disease occ…
Kendra Brett, Camille Dulong, Melissa Severn
…eing pulmonary TB.,Individuals with TB are categorized into latent TB infection (LTBI) and active TB disease., LTBI refers to an individual who has the M. tuberculosis infection in which the bacteria are alive but are not currently causing active TB disease. Active TB disease occ…
Zolelwa Sifumba
…d by mycobacteria that are resistant to standard first-line treatment, typically isoniazid and rifampicin (Seung et al., 2015). In 2023, MDR-TB caused an estimated 150,000 deaths globally, and over half of the global number of patients with MDR-TB were based in five countries: In…
David S.C. Hui, Chi Chiu Leung
…ion highlights the importance for developing more effective treatment modalities in order to reduce morbidity and mortality. In this contemporary concise review, articles related to these common respiratory infections and TB published recently in Respirology and selected articles…
Cynthia Bin Eng Chee, David S.C. Hui
…bration, we present an opinion on advances in diagnosis and treatment of these common respiratory infections. Influenza and CAP continue to be important. The availability of pneumococcal vaccines and multiplex polymerase chain reactions (PCR) has led to a decreasing incidence of …
Swinkels HM, Jilani TN, Tobin EH
…tory. Long considered an infection without a known cause or treatment, disease understanding has rapidly progressed. Robert Koch discovered the Mycobacterium tuberculosis bacterium (Mtb) in 1882, and, just over 100 years later, its complete genome sequence was mapped. Today, cont…
Simon Tiberi, Giovanni Battista Migliori, Jeremiah Chakaya, Tereza Kaesava, Seif Al-Abri, et al.
…nd-tb.Google Scholar) to: scale up access to prevention and treatment; build a multisectorial accountability; ensure sufficient and sustainable financing including research; promote an end to stigma and discrimination, and promote an equitable, rights-based and people-centered TB…
Migliori GB, Tiberi S, Tiberi S, Zumla A, Petersen E, et al.
…ntinuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from con…
Occhineri S, Matucci T, Rindi L, Tiseo G, Falcone M, et al.
…d Health Organization (WHO) determined to include PA in its guidelines for the treatment of rifampicin-resistant (RR), multi drug resistant (MDR) and pre-extensively drug resistant TB (pre-XDR-TB) with BDQ, LZD and Moxifloxacine (MFX) in a 6-month regimen. Although further studie…
Parveen U, Sultana S, Heba SF, Rafi R, Begum A, et al.
… TB in developing countries paved way to development of new guidelines for treating various form of tuberculosis. Furthermore, newer regimens are warranted to combat resistance that preferably cause a reduction in mortality. Until now, various ongoing trials are being carried in …
Hamidah Hussain, Amyn A. Malik
…Systematic Review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis.Clin Infect Dis. 2017; 64: 1670-1677Crossref PubMed Scopus (88) Google Scholar, 2Seddon JA Fred D Amanullah F et al.Post-exposure…
Anusha Gopinathan, Shweta Sagar Naik, K.V. Leela, Sujith Ravi
…ffairs in our country, despite there being well-established treatment regimens for tuberculosis over the last 50 years. The pitfalls of the drug regimens existent in India are the rigid and prolonged drug schedules with its frequent dosing, side effects, and poor patient complian…